{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T08:15:52Z","timestamp":1784448952070,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-025-05830-9","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:52:58Z","timestamp":1767930778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal mycological profiling of influenza-associated and COVID-19-associated pulmonary aspergillosis"],"prefix":"10.1186","volume":"30","author":[{"given":"Valentine","family":"Delanote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannes","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Moon","family":"Lauwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cato","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenn","family":"Maessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Frederiks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Meersseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Peetermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lore","family":"Vanderbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Wijngaerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Feys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"5830_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00151-6","author":"S Feys","year":"2024","unstructured":"Feys S. Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients. Lancet Respir Med. 2024. https:\/\/doi.org\/10.1016\/S2213-2600(24)00151-6.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"5830_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S2213-2600(22)00259-4","volume":"10","author":"S Feys","year":"2022","unstructured":"Feys S, et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med. 2022;10(12):1147\u201359. https:\/\/doi.org\/10.1016\/S2213-2600(22)00259-4.","journal-title":"Lancet Respir Med"},{"key":"5830_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06091-6","author":"PE Verweij","year":"2020","unstructured":"Verweij PE. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020. https:\/\/doi.org\/10.1007\/s00134-020-06091-6.","journal-title":"Intensive Care Med"},{"issue":"10","key":"5830_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782\u201392. https:\/\/doi.org\/10.1016\/S2213-2600(18)30274-1.","journal-title":"Lancet Respir Med"},{"key":"5830_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30847-1","author":"P Koehler","year":"2021","unstructured":"Koehler P. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(20)30847-1.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5830_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","volume":"177","author":"W Meersseman","year":"2008","unstructured":"Meersseman W, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177(1):27\u201334. https:\/\/doi.org\/10.1164\/rccm.200704-606OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5830_CR7","unstructured":"Bartoletti M et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study, Dec. 06, 2021, Clin Infect Dis."},{"key":"5830_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043347","author":"M Zou","year":"2012","unstructured":"Zou M et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive Aspergillosis. PLoS One. 2012. . https:\/\/doi.org\/10.1371\/journal.pone.0043347","journal-title":"PLoS One"},{"key":"5830_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00661","author":"T Mercier","year":"2018","unstructured":"Mercier T, Guldentops E, Lagrou K, Maertens J. Galactomannan, a surrogate marker for outcome in invasive aspergillosis: finally coming of age. Front Microbiol. 2018. https:\/\/doi.org\/10.3389\/fmicb.2018.00661.","journal-title":"Front Microbiol"},{"issue":"4","key":"5830_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1128\/JCM.02281-09","volume":"48","author":"S Koo","year":"2010","unstructured":"Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol. 2010;48(4):1255\u201360. https:\/\/doi.org\/10.1128\/JCM.02281-09.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"5830_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/cncr.22863","volume":"110","author":"G Woods","year":"2007","unstructured":"Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer. 2007;110(4):830\u20134. https:\/\/doi.org\/10.1002\/cncr.22863.","journal-title":"Cancer"},{"issue":"7","key":"5830_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1086\/339324","volume":"34","author":"B Fran\u00e7ois","year":"2002","unstructured":"Fran\u00e7ois B, et al. Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease. Clinical Infectious Diseases. 2002;34(7):939\u201343. https:\/\/doi.org\/10.1086\/339324.","journal-title":"Clinical Infectious Diseases."},{"issue":"2","key":"5830_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.24022","volume":"115","author":"J Maertens","year":"2009","unstructured":"Maertens J, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 2009;115(2):355\u201362. https:\/\/doi.org\/10.1002\/cncr.24022.","journal-title":"Cancer"},{"key":"5830_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae114","author":"DZP Friedman","year":"2024","unstructured":"Friedman DZP, Theel ES, Walker RC, Vikram HR, Razonable RR, Vergidis P. Serial bronchoalveolar lavage fluid aspergillus galactomannan and treatment response in invasive pulmonary aspergillosis. Open Forum Infect Dis. 2024. https:\/\/doi.org\/10.1093\/ofid\/ofae114.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"5830_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1164\/rccm.202401-0145OC","volume":"210","author":"S Feys","year":"2024","unstructured":"Feys S, et al. Profiling bacteria in the lungs of patients with severe influenza versus COVID-19 with or without aspergillosis. Am J Respir Crit Care Med. 2024;210(10):1230\u201342. https:\/\/doi.org\/10.1164\/rccm.202401-0145OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"5830_CR16","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3201\/eid2711.211174","volume":"27","author":"NAF Janssen","year":"2021","unstructured":"Janssen NAF, et al. Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis1. Emerg Infect Dis. 2021;27(11):2892\u20138. https:\/\/doi.org\/10.3201\/eid2711.211174.","journal-title":"Emerg Infect Dis"},{"key":"5830_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06510-2","author":"J Prattes","year":"2021","unstructured":"Prattes J, et al. COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. Intensive Care Med. 2021. https:\/\/doi.org\/10.1007\/s00134-021-06510-2.","journal-title":"Intensive Care Med"},{"issue":"2","key":"5830_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","volume":"10","author":"JP Gangneux","year":"2022","unstructured":"Gangneux JP, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022;10(2):180\u201390. https:\/\/doi.org\/10.1016\/S2213-2600(21)00442-2.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"5830_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00134-021-06431-0","volume":"47","author":"L Vanderbeke","year":"2021","unstructured":"Vanderbeke L, et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. 2021;47(6):674\u201386. https:\/\/doi.org\/10.1007\/s00134-021-06431-0.","journal-title":"Intensive Care Med"},{"key":"5830_CR20","doi-asserted-by":"publisher","unstructured":"Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. Feb. 2021;384(8):693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","DOI":"10.1056\/NEJMoa2021436"},{"issue":"3","key":"5830_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-2600(23)00408-3","volume":"12","author":"F Gioia","year":"2024","unstructured":"Gioia F, Walti LN, Orchanian-Cheff A, Husain S. Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Lancet Respir Med. 2024;12(3):207\u201316. https:\/\/doi.org\/10.1016\/S2213-2600(23)00408-3.","journal-title":"Lancet Respir Med"},{"key":"5830_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85644-5","author":"S Dubler","year":"2025","unstructured":"Dubler S. Implications for the diagnosis of aspiration and aspergillosis in critically ill patients with detection of galactomannan in broncho-alveolar lavage fluids. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-025-85644-5.","journal-title":"Sci Rep"},{"key":"5830_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.02298-21","author":"DR Giacobbe","year":"2022","unstructured":"Giacobbe DR, et al. Prognostic impact of bronchoalveolar lavage fluid galactomannan and Aspergillus culture results on survival in COVID-19 intensive care unit patients: a post hoc analysis from the European confederation of medical mycology (ECMM) COVID-19-associated pulmonary aspergillosis study. J Clin Microbiol. 2022. https:\/\/doi.org\/10.1128\/jcm.02298-21.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"5830_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1164\/rccm.202208-1570OC","volume":"208","author":"L Vanderbeke","year":"2023","unstructured":"Vanderbeke L, et al. A pathology-based case series of influenza- and COVID-19\u2013associated pulmonary aspergillosis - the proof is in the tissue. Am J Respir Crit Care Med. 2023;208(3):301\u201311. https:\/\/doi.org\/10.1164\/rccm.202208-1570OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"5830_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2300-x","author":"Y Yu","year":"2019","unstructured":"Yu Y. Bronchoalveolar lavage fluid dilution in ICU patients: what we should know and what we should do. Crit Care. 2019. https:\/\/doi.org\/10.1186\/s13054-018-2300-x.","journal-title":"Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05830-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:04:32Z","timestamp":1770642272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-025-05830-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5830"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05830-9","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of University Hospitals Leuven (protocol number S65588; sub-study approval as stated in the manuscript). Given the retrospective design and use of anonymized clinical data, there was no need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.F. received travel grants from Pfizer and Gilead, funding for a public doctoral defence from Pfizer, Gilead, and Mundipharma, and has received a speaker\u2019s fee from Healthbook Company Ltd. J.W. also received investigator-initiated grants, travel grants and speakers fees from Pfizer, MSD, and Gilead and has received a speaker\u2019s fee from Mundipharma and Astra Zeneca. J.W. was supported by BOF-ZAP funding of KU Leuven and by the EU Horizon 2020 HDMFUN research project. K.L. received consultancy fees from Mundipharma, speaker fees from Pfizer, Gilead, Mundipharma, and FUJIFILM Wako Chemicals Europe GmbH; a service fee from TECOmedical; a fee for Advisory Board participation from Pfizer; and travel support from Pfizer, Gilead, and AstraZeneca. Y.D. and M.P. received travel grants from Pfizer. J.H. received FWO fundamental research grant (11PBR24N) and travel grants from Gilead. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}